功能性胰岛素阿斯巴特/胰岛素脱脂基微针,用于促进食后血糖控制
Bo Zhi Chen1, Wen Xuan Li1, Yun Hao Feng1
1State Key Laboratory of Organic-Inorganic Composites, Beijing University of Chemical Technology, Beijing 100029, China; Beijing Laboratory of Biomedical Materials, College of Materials Science and Engineering, Beijing University of Chemical Technology, Beijing 100029, China.
Acta biomaterialia
|September 14, 2023
概括
溶解装有胰岛素阿斯巴尔特或胰岛素降糖的微针,为糖尿病管理提供了每日注射的无痛替代方案. 这些微针有效控制血糖,可能提高患者的服从性和方便性.
科学领域:
- 生物材料科学 生物材料科学
- 内分泌学 在内分泌学.
- 制药科学 制药科学
背景情况:
- 第三代胰岛素,如胰岛素阿斯巴特 (IAsp) 和胰岛素降糖 (IDeg) 提供了改善的药理动力学特征.
- 微针 (MNs) 是一种通过皮肤递送药物系统,可以减少注射疼痛并改善患者的服药性.
- 目前的糖尿病管理通常涉及每天多次注射胰岛素,这对患者来说可能是负担.
研究的目的:
- 调查使用溶解微针用于通过皮肤输送IAsp和IDeg的可行性.
- 评估含胰岛素的微针在控制糖尿病大鼠血糖水平方面的疗效.
- 评估基于微针的胰岛素治疗作为每日注射的替代品的潜力.
主要方法:
- 用IAsp或IDeg装载的溶解微针的制造和特征.
- 评估微针的机械性能,结构稳定性和透皮应用特征.
- 在微针应用后,在各种饮食条件和应用策略下,对糖尿病大鼠的血糖控制的体内评估.
- 模拟分子动力学以研究胰岛素-微针矩阵相互作用.
主要成果:
- 装有胰岛素的微针显示,血糖控制与糖尿病大鼠的皮下注射相当.
- 微针系统有效地模仿了对食物的反应中的生理胰岛素分泌模式.
- 机械和稳定性测试证实了载有胰岛素的微针在透皮治疗中的实用性.
- 模拟提供了对微针矩阵内的药物稳定性和释放机制的见解.
结论:
- 装有IAsp或IDeg的溶解微针是每天多次注射胰岛素的一个有希望的替代方案.
- 这项技术有可能改善血糖控制,降低低血糖风险,并提高患者的便利性.
- 需要进一步的研究和临床试验来支持这种基于微针的疗法的转化.
相关概念视频
Insulin Formulations: Types and Delivery
225
Insulin preparations are categorized by their duration of action into short-acting and long-acting types. Two strategies are used to modify insulin's absorption and pharmacokinetic profile: slowing the absorption post-subcutaneous injection, or altering human insulin's amino acid sequence or protein structure. These changes retain the insulin's ability to bind to the insulin receptor, but alter its behavior in solution or after injection.
Short-acting insulins are divided into...
Short-acting insulins are divided into...
225
Oral Hypoglycemic Agents: Glinides
183
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
183
Insulin: Dosing Regimen and Adverse Effects
205
Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
205
Glucagon-like Receptor Agonists
357
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
357
Dipeptidyl Peptidase 4 Inhibitors
211
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
211
Insulin: Biosynthesis, Chemistry, and Preparation
422
The endoplasmic reticulum (ER) of pancreatic β-cells synthesizes preproinsulin, which consists of a signal peptide, A and B chains, and a C-peptide. Preproinsulin is then cleaved and folded into proinsulin, which translocates to the Golgi apparatus for sorting and packaging into secretory granules. In these granules, enzymatic clipping generates insulin and C-peptide.
Damage or functional impairment of β-cells inhibits insulin production, leading to diabetes. Diabetes treatment...
Damage or functional impairment of β-cells inhibits insulin production, leading to diabetes. Diabetes treatment...
422


